MedTrace Logo

Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

NCT01169792 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2010-07-26

No results posted yet for this study

Summary

The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen.

The investigators want to

* evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and
* analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.

Conditions

  • Breast Neoplasms
  • Survival Analysis
  • Antineoplastic Agents
  • Therapeutic Uses

Interventions

DRUG

tamoxifen

Sponsors & Collaborators

  • Inje University

    collaborator OTHER

  • Yonsei University

    lead OTHER

Principal Investigators

  • Byeong-Woo Park, M.D.,ph.D. · Department of Surgery and Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine

  • Jae-Gook Shin, M.D.,ph.D. · Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01169792 on ClinicalTrials.gov